[Antimigrainous agents used in maintenance treatment].
Massiou
H
H
Bousser
M G
MG
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000639:Amitriptyline / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001584:Benzoxepins / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002936:Cinnarizine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003000:Clonidine / Q000627:therapeutic use; D004087:Dihydroergotamine / Q000627:therapeutic use; D005444:Flunarizine; D006801:Humans; D008784:Methysergide / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy*; D010918:Pizotyline / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D001584:Benzoxepins; D002121:Calcium Channel Blockers; D010918:Pizotyline; D000639:Amitriptyline; D002936:Cinnarizine; D004087:Dihydroergotamine; D011433:Propranolol; D003000:Clonidine; D001241:Aspirin; D005444:Flunarizine; C011962:oxetorone; D008784:Methysergide
Les antimigraineux utilisés dans le traitement de fond.